KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Weighted Average) (2016 - 2025)

Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.24% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 1.24%, and an annual FY2025 reading of $1.1 billion, up 1.24% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.1 billion at Teva Pharmaceutical Industries, roughly flat from $1.1 billion in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $1.1 billion in Q2 2025, with the low at $1.1 billion in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 0.55% in 2021 and then grew 1.34% in 2025.
  • Tracing TEVA's Shares Outstanding (Weighted Average) over 5 years: stood at $1.1 billion in 2021, then rose by 0.73% to $1.1 billion in 2022, then increased by 0.81% to $1.1 billion in 2023, then rose by 1.07% to $1.1 billion in 2024, then grew by 1.24% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Shares Outstanding (Weighted Average) are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).